Skip to main content
OpenTrials
Completed

NCT Number: NCT05910437

Optimizing Treatments for Heart Failure During Hospitalization

Heart failure reaches 1.5 million people in France and is responsible for 200,000 hospitalizations per year.

Over the past ten years, new therapies have emerged (treatment of martial deficiency, Entresto, iSGLT2).

Hospitalization in a context of acute heart failure is a moment of choice in the history of the disease to introduce recommended treatments under closer supervision (clinical, biological) than in ambulatory, and allows a decrease in hospitalizations, morbidity and mortality.

The purpose of this study is to describe the introduction of heart failure drugs (including iSGLT2) in real-life settings in patients hospitalized for decompensated heart failure.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Decompensated Heart Failure

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chr Metz Thionville, Ars-Laquenexy, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient ≥ 18 years
  • Hospitalized (≥24h) for decompensated heart failure in cardiology.

Exclusion criteria

  • Patient opposition participation in research and use of data.

Treatment and study plan

Hospitalized patient for decompensated heart failure

Other

Describe the evolution of heart failure medications during hospitalization for decompensated heart failure.

Primary outcomes

  1. Prescription score

    Time frame: During hospitalisation for decompensated heart failure (up to 10 days)

    Prescription score, ranging from 0 to 10, each type of heart failure treatment (IEC/ARA2, Sacubitril, betablockers, SGLT2i, MRA) being evaluated on a scale of 2.

Secondary outcomes

  1. serum concentration of creatinine

    Time frame: During hospitalisation for decompensated heart failure (up to10 days)

    Creatinine measured at admission and discharge

  2. serum concentration of potassium

    Time frame: During hospitalisation for decompensated heart failure (up to 10 days)

    Potassium measured at admission and discharge

  3. Concentration of hemoglobin

    Time frame: During hospitalisation for decompensated heart failure (up to 10 days)

    hemoglobin measured at admission and discharge

  4. All cause Death

    Time frame: 6 months

  5. Rate of hospitalization for heart failure

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Acronym: OPTICARD

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Jun 18, 2023
Registry last updated
Feb 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.